Company: MBIO
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001104659-25-032236
Chunk: 16

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-04
Form: POS AM
Chunk 16
---
 breaches of their fiduciary duty to the corporation, except under certain circumstances, including a breach
of the director’s duty of loyalty, acts or omissions of the director not in good faith or which involve intentional misconduct or
a knowing violation of law, the approval of an improper payment of a dividend or an improper purchase by the corporation of stock or any
transaction from which the director derived an improper personal benefit. Our amended and restated Certificate of Incorporation, as amended,
eliminates the personal liability of directors to us or our stockholders for monetary damages for breach of fiduciary duty as a director
with certain limited exceptions set forth in the DGCL.

Section 145 of the DGCL grants to corporations
the power to indemnify each officer and director against liabilities and expenses incurred by reason of the fact that he or she is or
was an officer or director of the corporation if he or she acted in good faith and in a manner he or she reasonably believed to be in
or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause
to believe his or her conduct was unlawful. Our amended and restated certificate of incorporation, as amended, and amended and restated
bylaws, as amended, provide for indemnification of each of our officers and directors to the fullest extent permitted by the DGCL. Section 145
of the DGCL also empowers corporations to purchase and maintain insurance on behalf of any person who is or was an officer or director
of the corporation against liability asserted against or incurred by him in any such capacity, whether or not the corporation would have
the power to indemnify such officer or director against such liability under the provisions of Section 145 of the DGCL.

Item 15. Recent Sales of Unregistered Securities.

The following list sets forth information as to
all unregistered securities we have sold since January 1, 2022 through the date of the prospectus that is a part of this registration
statement:

October 2023 Private Placement

On October 26, 2023, we entered into a Securities
Purchase Agreement (the “Purchase Agreement”) with an institutional accredited investor, for a private placement offering
of warrants to purchase 51,764 shares of common stock. Pursuant to the Purchase Agreement, we agreed to issue and sell the warrants at
an offering price of $5.25 per warrant to purchase one share of common stock. The warrants have an exercise price of $79